SCHEMBL1695203

SCHEMBL1695203

C/C(=N\O)c1cc2c(F)cccc2nc1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.37
ESR2 Q92731 1/20 0.37
MGLL Q99685 1/20 0.37
KDM4E B2RXH2 4/20 0.37
MAPT P10636 3/20 0.37
ALDH1A1 P00352 3/20 0.37
CYP1A2 P05177 2/20 0.37
SMN1; SMN2 Q16637 3/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
GPR3 P46089 1/20 0.35
TP53 P04637 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MEN1 O00255 4/20 0.34
KMT2A Q03164 4/20 0.34
PDE10A Q9Y233 2/20 0.34
LMNA P02545 1/20 0.34
HTT P42858 1/20 0.33
POLB P06746 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14815893 1.00 ESR1 (0.37) ESR1ESR2MGLLKDM4EMAPT
SCHEMBL14815892 1.00 ESR1 (0.37) ESR1ESR2MGLLKDM4EMAPT
SCHEMBL1695174 0.82 SMN1; SMN2 (0.50) ESR1ESR2KDM4EMAPTALDH1A1
SCHEMBL3770305 0.78 ESR1 (0.38) ESR1ESR2MGLLKDM4EMAPT
SCHEMBL3770307 0.78 ESR1 (0.38) ESR1ESR2MGLLKDM4EMAPT
SCHEMBL2717594 0.78 ESR1 (0.38) ESR1ESR2MGLLKDM4EMAPT
SCHEMBL13017492 0.76 ALDH1A1 (0.53) KDM4EMAPTALDH1A1CYP1A2SMN1; SMN2
SCHEMBL15660706 0.74 ALDH1A1 (0.55) KDM4EALDH1A1CYP1A2SMN1; SMN2RAB9A
SCHEMBL24950821 0.73 TSHR (0.60) KDM4EALDH1A1CYP1A2SMN1; SMN2NPC1
SCHEMBL31133620 0.73 TSHR (0.60) KDM4EALDH1A1CYP1A2SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2588467-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY Amgen Inc. (US) 2013-05-08 EP disclosed
US-20130085131-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-04 US disclosed
US-20130085131-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-04 US disclosed
US-20130085131-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-04 US disclosed
WO-2012003274-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed
WO-2012003274-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085131-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, SSB, BCL9 ESR1 1445/4885ESR2 426/4885MGLL 1388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.